Mangalam Drugs And Organics growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−27.1%−13.7%—
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−141.6%+105.9%—
−272.4%+599.8%—
−760.6%+174.1%—
−760.0%+174.2%—
−14.0%+9.9%−7.3%
−30.8%+9.7%—
−90.2%+484.7%−128.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANGALAM₹29.22

Mangalam Drugs And Organics Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹46.3 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth——-13.7-27.1—
EBITDA Growth——+105.9-141.6—
EBIT Growth——+599.8-272.4—
Net Income Growth——+174.1-760.6—
EPS Growth——+174.2-760.0—
Total Assets Growth—-7.3+9.9-14.0—
Total Equity Growth——+9.7-30.8—
Cash from Operations Growth—-128.0+484.7-90.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.